M
Mary Akinola
Publications - 3
Citations - 335
Mary Akinola is an academic researcher. The author has contributed to research in topics: Positron emission tomography & Memantine. The author has an hindex of 3, co-authored 3 publications receiving 263 citations.
Papers
More filters
Journal ArticleDOI
Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density
Craig Curtis,Jose Gamez,Upinder Singh,Carl H. Sadowsky,Teresa Villena,Marwan N. Sabbagh,Thomas G. Beach,Ranjan Duara,Adam S. Fleisher,Adam S. Fleisher,Kirk A. Frey,Zuzana Walker,Zuzana Walker,Arvinder Hunjan,Clive Holmes,Yavir M. Escovar,Carla X. Vera,Marc Agronin,Joel Ross,Andrea Bozoki,Mary Akinola,Jiong Shi,Rik Vandenberghe,Milos D. Ikonomovic,Paul Sherwin,Igor D. Grachev,Igor D. Grachev,G. Farrar,Adrian Smith,Christopher Buckley,Richard McLain,Stephen Salloway,Stephen Salloway +32 more
TL;DR: This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population and may increase diagnostic accuracy in cognitively impaired patients.
Journal ArticleDOI
Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
Stephen Salloway,Jose Gamez,Upinder Singh,Carl H. Sadowsky,Teresa Villena,Marwan N. Sabbagh,Thomas G. Beach,Ranjan Duara,Adam S. Fleisher,Kirk A. Frey,Zuzana Walker,Arvinder Hunjan,Yavir M. Escovar,Marc Agronin,Joel Ross,Andrea Bozoki,Mary Akinola,Jiong Shi,Rik Vandenberghe,Milos D. Ikonomovic,Paul Sherwin,Gill Farrar,Adrian Smith,Christopher Buckley,Dietmar Rudolf Thal,Michelle Zanette,Craig Curtis +26 more
TL;DR: Performance of the amyloid tracer [18F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques and CERAD “ original” and “modified”.
Journal ArticleDOI
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Clive Ballard,Alan J. Thomas,Stephen Gerry,Ly-Mee Yu,Dag Aarsland,C Merritt,Anne Corbett,C Davison,N Sharma,Zunera Khan,Byron Creese,P Loughlin,C Bannister,Alistair Burns,S N Win,Zuzana Walker,Nicola Ferreira,Paul Koranteng,R Vanderputt,Mary Akinola,L Martos,Jessica Adams,C Dransfield,M Pavey,N Collicott,C Hall,L Rigby,L D Warr,M Leontis,S Shora,S Bhan-Kotwal +30 more
TL;DR: This study indicates no benefits for memantine in the long-term treatment and prophylaxis of clinically significant neuropsychiatric symptoms, but the results did indicate some benefits for antipsychotic medications in reducing the relapse of neuroPsychiatric symptoms.